430 related articles for article (PubMed ID: 28221729)
1. Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation.
Berry JL; Kogachi K; Aziz HA; McGovern K; Zolfaghari E; Murphree AL; Jubran R; Kim JW
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 28221729
[TBL] [Abstract][Full Text] [Related]
2. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
3. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
4. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage.
Berry JL; Jubran R; Kim JW; Wong K; Bababeygy SR; Almarzouki H; Lee TC; Murphree AL
Pediatr Blood Cancer; 2013 Apr; 60(4):688-93. PubMed ID: 22997170
[TBL] [Abstract][Full Text] [Related]
6. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
Shields CL; Shields JA; Needle M; de Potter P; Kheterpal S; Hamada A; Meadows AT
Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
[TBL] [Abstract][Full Text] [Related]
7. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Trans Am Ophthalmol Soc; 2004; 102():35-44; discussion 44-5. PubMed ID: 15747743
[TBL] [Abstract][Full Text] [Related]
8. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
9. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
10. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
11. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma.
Brichard B; De Bruycker JJ; De Potter P; Neven B; Vermylen C; Cornu G
Med Pediatr Oncol; 2002 Jun; 38(6):411-5. PubMed ID: 11984802
[TBL] [Abstract][Full Text] [Related]
12. Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma.
Zhao J; Feng ZX; Wei M; Liu G; Solarte CE; Li B; Wang Y; Zhang C; Gallie BL
Ophthalmol Retina; 2020 Jun; 4(6):630-639. PubMed ID: 32387053
[TBL] [Abstract][Full Text] [Related]
13. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina.
Chantada GL; Fandiño AC; Schvartzman E; Raslawski E; Schaiquevich P; Manzitti J
Pediatr Blood Cancer; 2014 May; 61(5):821-6. PubMed ID: 24243706
[TBL] [Abstract][Full Text] [Related]
14. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
Gündüz K; Shields CL; Shields JA; Meadows AT; Gross N; Cater J; Needle M
Arch Ophthalmol; 1998 Dec; 116(12):1613-7. PubMed ID: 9869790
[TBL] [Abstract][Full Text] [Related]
15. Enucleation vs Ophthalmic Artery Chemosurgery for Advanced Intraocular Retinoblastoma: A Retrospective Analysis.
Yannuzzi NA; Francis JH; Marr BP; Belinsky I; Dunkel IJ; Gobin YP; Abramson DH
JAMA Ophthalmol; 2015 Sep; 133(9):1062-6. PubMed ID: 26181236
[TBL] [Abstract][Full Text] [Related]
16. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
17. Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.
Brennan RC; Qaddoumi I; Billups CA; Free TL; Haik BG; Rodriguez-Galindo C; Wilson MW
Br J Ophthalmol; 2015 Oct; 99(10):1366-71. PubMed ID: 25873648
[TBL] [Abstract][Full Text] [Related]
18. Chemoreduction for intraocular retinoblastoma in Malaysia.
Menon BS; Juraida E; Alagaratnam J; Mohammad M; Ibrahim H; George TM; Ariffin H; Ho C; Khuzaiah R; Peng LH
J Pediatr Hematol Oncol; 2007 Jan; 29(1):2-4. PubMed ID: 17230058
[TBL] [Abstract][Full Text] [Related]
19. [Clinical therapeutic efficiency of chemoreduction and local therapy for children with retinoblastoma].
Qian J; Xue K; Gao YJ; Yuan YF; Shan HD; Bi YW
Zhonghua Yan Ke Za Zhi; 2010 Apr; 46(4):312-6. PubMed ID: 20654057
[TBL] [Abstract][Full Text] [Related]
20. Patterns of subretinal fluid resolution in Group D eyes treated with chemoreduction: Experience from the Children's Hospital Los Angeles/University of Southern California.
Berry JL; Shih G; Moysidis SN; Jubran R; Wong K; Lee TC; Murphree AL; Kim JW
Ophthalmic Genet; 2016 Dec; 37(4):400-403. PubMed ID: 26934665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
